Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...183184185186187188189190191192193...208209»
  • ||||||||||  Promising targeted approaches (Helsinki 2) -  Sep 30, 2019 - Abstract #DGHO2019DGHO_1214;    
    The combination of trifluridine/tipiracil (TAS-102) is a new oral anticancer drug with activity in gastrointestinal cancer...Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits the VEGFR-2 tyrosine kinase...The recent results from a large phase 3 trial with andecaliximab, a monoclonal antibody that inhibits matrix-metalloproteinase-9 (MMP-9), failed to replicate the positive data from a previous study of andecaliximab in combination with chemotherapy in untreated HER2-negative gastric or gastroesophageal junction adenocarcinoma...Randomized clinical studies with zolbetuximab are ongoing. Data on new targeted therapy options (excluding immunotherapy) will be discussed.
  • ||||||||||  camrelizumab (INCSHR1210) / Incyte
    Clinical, Journal:  Camrelizumab: First Global Approval. (Pubmed Central) -  Sep 30, 2019   
    The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer. This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma.
  • ||||||||||  HTI-1090 / Jiangsu Hengrui Pharma
    Trial completion date:  A Trial of HTI-1090 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Sep 29, 2019   
    P1,  N=18, Completed, 
    This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma. Trial completion date: Jul 2019 --> Jan 2019
  • ||||||||||  AiTan (rivoceranib) / LSK BioPartners, Cyramza (ramucirumab) / Eli Lilly
    Review, Journal:  Tumor progression-dependent angiogenesis in gastric cancer and its potential application. (Pubmed Central) -  Sep 29, 2019   
    In phase III clinical trials, only ramucirumab (anti-VEGFR blocker) and apatinib (VEGFR-TKI blocker) have reported an improved median overall response rate and prolonged OS and progression-free survival outcomes as a 2nd-line agent combined with chemotherapy treatment in advanced GC. By providing insights into the molecular mechanisms of angiogenesis associated with tumor progression in GC, this review will hopefully aid the optimization of antiangiogenesis strategies for GC therapy in combination with chemotherapy and adjuvant treatment.
  • ||||||||||  AiTan (rivoceranib) / LSK BioPartners
    Retrospective data, Journal:  Apatinib as an optional treatment in metastatic colorectal cancer. (Pubmed Central) -  Sep 27, 2019   
    Multivariate analysis indicated previous antiangiogenic therapy and baseline elevated neutrophil-to-lymphocyte ratio (NLR) as independent prognostic factors.Apatinib might be a reasonable treatment option with a controlled safety profile for patients with mCRC who have failed standard therapy. Patients who previously received antiangiogenic therapy and who have baseline elevated NLR are more likely to benefit from apatinib.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, PD(L)-1 Biomarker, IO biomarker:  PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma (clinicaltrials.gov) -  Sep 19, 2019   
    P2,  N=30, Recruiting, 
    It indicated that apatinib may be a superior choice for advanced ovarian cancer patients, but further prospective studies are needed to optimize the treatment. Not yet recruiting --> Recruiting
  • ||||||||||  Tykerb (lapatinib) / Novartis, pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
    Journal:  Pyrotinib Tops Lapatinib in Metastatic Breast Cancer. (Pubmed Central) -  Sep 19, 2019   
    Pyrotinib did increase the incidence of side effects such as diarrhea and hand-foot syndrome. However, about 54% of trial participants had previously taken trastuzumab, so the study's results may not hold true in the United States, where most patients receive it.
  • ||||||||||  AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Sep 19, 2019   
    P1,  N=30, Completed, 
    However, about 54% of trial participants had previously taken trastuzumab, so the study's results may not hold true in the United States, where most patients receive it. Active, not recruiting --> Completed | Trial completion date: Sep 2019 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Mar 2019